| Celgeneannounced 30 Jul 2019 |
Submit an sNDA for POMALYST |
No record found31 Dec 2019 |
| Celgeneannounced 30 Jul 2019 |
Submit the BLA for ide-cel |
No record found30 Jun 2020 |
| Celgeneannounced 25 Apr 2019 |
Submit the BLA for liso-cel in non-Hodgkin lymphoma to the FDA |
No record found31 Dec 2019 |
| Celgeneannounced 25 Apr 2019 |
Submit the EU MAA for fedratinib |
No record found31 Dec 2019 |
| Celgeneannounced 31 Jan 2019 |
Submit Ozanimod regulatory applications in the U.S. and EU |
Met31 Mar 2019 |
| Celgeneannounced 25 Oct 2018 |
Initiate the phase III ADVANCE™ trial for OTEZLA® |
Late31 Dec 2018 |
| Celgeneannounced 9 Jul 2018 |
Submit data from BELIEVE and MEDALIST studies to a medical meeting |
No record found31 Dec 2018 |
| Celgeneannounced 28 Jun 2018 |
Submit MEDALIST trial data to a medical meeting |
No record found31 Dec 2018 |
| Celgeneannounced 4 May 2018 |
Initiate the pivotal program for OTEZLA in ulcerative colitis |
Not met31 Dec 2018 |
| Celgeneannounced 4 May 2018 |
Submit NDA and MAA for ozanimod in relapsing multiple sclerosis |
Met31 Mar 2019 |
| Celgeneannounced 25 Jan 2018 |
Close the acquisition of Impact Biomedicines |
Met31 Mar 2018 |
| Celgeneannounced 25 Jan 2018 |
Report data from the phase III MEDALIST and BELIEVE trials |
Partly met30 Jun 2018 |
| Celgeneannounced 25 Jan 2018 |
Initiate the TRANSCEND WORLD cohort |
Met30 Jun 2018 |
| Celgeneannounced 25 Jan 2018 |
Initiate the phase III COMMANDS trial with luspatercept |
Late30 Jun 2018 |
| Celgeneannounced 22 Jan 2018 |
Close the acquisition of Juno Therapeutics |
Met31 Mar 2018 |
| Celgeneannounced 22 Jan 2018 |
Initiate Phase II TRANSCEND WORLD trial |
Met31 Dec 2018 |
| Celgeneannounced 22 Jan 2018 |
Initiate POC trial for CC-486 |
Met31 Dec 2018 |
| Celgeneannounced 22 Jan 2018 |
Initiate Phase II PILOT trial |
No record found31 Dec 2018 |
| Celgeneannounced 22 Jan 2018 |
Initiate Phase II combo trial with ibrutinib |
No record found31 Dec 2018 |
| Celgeneannounced 22 Jan 2018 |
Initiate Phase I/II 2nd line trial |
No record found31 Dec 2018 |
| Celgeneannounced 22 Jan 2018 |
Initiate pivotal program for CC-122 |
No record found31 Dec 2018 |
| Celgeneannounced 26 Oct 2017 |
Submit a New Drug Application to the FDA for ozanimod in relapsing multiple sclerosis |
Met31 Dec 2017 |
| Celgeneannounced 26 Oct 2017 |
Begin a pivotal trial for bb2121 in relapsed and/or refractory multiple myeloma |
Met31 Dec 2017 |
| Celgeneannounced 26 Oct 2017 |
Complete enrollment for the phase III TRUE NORTH trial evaluating ozanimod in ulcerative colitis |
Not met31 Dec 2018 |
| Celgeneannounced 22 May 2017 |
Submit a New Drug Application to the U.S. Food and Drug Administration for ozanimod |
Met31 Dec 2017 |
| Celgeneannounced 22 May 2017 |
Submit global registration dossiers for ozanimod |
Met31 Dec 2017 |
| Celgeneannounced 27 Apr 2017 |
Present phase IIa trial data for CC-220 |
Met30 Jun 2017 |
| Celgeneannounced 27 Apr 2017 |
Present updated data from the phase I/II trial evaluating IDHIFA |
Met30 Jun 2017 |
| Celgeneannounced 27 Apr 2017 |
Initiate phase III trial in scalp psoriasis |
Met30 Jun 2017 |
| Celgeneannounced 27 Apr 2017 |
Initiate phase IIb trial with CC-220 |
No record found31 Dec 2017 |
| Celgeneannounced 27 Apr 2017 |
Initiate phase III trial with ozanimod in Crohn’s disease |
Not met31 Dec 2017 |
| Celgeneannounced 27 Apr 2017 |
Initiate pivotal trial with bb2121 in RRMM |
Met31 Dec 2017 |
| Celgeneannounced 27 Apr 2017 |
Present STEPSTONE trial data at a medical congress |
No record found31 Dec 2017 |
| Celgeneannounced 27 Apr 2017 |
Initiate pivotal trial with JCAR017 in NHL |
Met · disputed31 Dec 2017 |
| Celgeneannounced 27 Apr 2017 |
Initiate phase III trial with luspatercept in first-line, lower-risk MDS |
Late31 Mar 2018 |
| Celgeneannounced 27 Oct 2016 |
Submit a new drug application for enasidenib |
Met31 Dec 2016 |
| Celgeneannounced 27 Oct 2016 |
Present data from the abound program of ABRAXANE in NSCLC |
Met31 Dec 2016 |
| Celgeneannounced 27 Oct 2016 |
Present data from the phase Ib trial of GED-0301 at the AIBD meeting |
No record found31 Dec 2016 |
| Celgeneannounced 27 Oct 2016 |
File an Investigational New Drug application for EM901 |
No record found31 Dec 2017 |
| Celgeneannounced 27 Oct 2016 |
Report data from the phase III program for GED-0301 |
No record found31 Dec 2018 |
| Celgeneannounced 12 Sep 2016 |
Present full 12-week data from the CD-001 trial at a scientific meeting |
No record found31 Dec 2016 |
| Celgeneannounced 28 Jul 2016 |
Submit an application for REVLIMID maintenance treatment in the U.S |
Met31 Dec 2016 |
| Celgeneannounced 28 Jul 2016 |
Report top-line data from the 12-week portion of the GED-0301 trial |
No record found31 Dec 2016 |
| Celgeneannounced 28 Apr 2016 |
Present meta-analysis of overall survival in patients treated with REVLIMID® maintenance at ASCO |
Met30 Jun 2016 |
| Celgeneannounced 28 Apr 2016 |
Present data from the apact® trial |
Not met31 Dec 2017 |
| Celgeneannounced 28 Apr 2016 |
Complete data analysis for the SUNBEAM and RADIANCE trials |
Met31 Dec 2017 |
| Celgeneannounced 28 Apr 2016 |
Present data from the TRUE NORTH trial |
Not met31 Dec 2018 |